Universal Beteiligungs und Servicegesellschaft mbH Invests $1.21 Million in Viridian Therapeutics, Inc. $VRDN

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 4th quarter, Holdings Channel reports. The firm bought 38,854 shares of the company’s stock, valued at approximately $1,209,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new position in shares of Viridian Therapeutics in the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC boosted its holdings in shares of Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after acquiring an additional 1,491 shares in the last quarter. Bessemer Group Inc. boosted its holdings in shares of Viridian Therapeutics by 947.7% in the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after acquiring an additional 1,886 shares in the last quarter. Larson Financial Group LLC acquired a new position in shares of Viridian Therapeutics in the 3rd quarter worth approximately $52,000. Finally, US Bancorp DE boosted its holdings in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after acquiring an additional 463 shares in the last quarter.

Viridian Therapeutics Stock Down 0.4%

NASDAQ:VRDN opened at $13.42 on Friday. The stock’s fifty day moving average price is $22.20 and its two-hundred day moving average price is $27.01. Viridian Therapeutics, Inc. has a 52-week low of $11.76 and a 52-week high of $34.29. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -4.08 and a beta of 0.82.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $15.75 million. On average, analysts anticipate that Viridian Therapeutics, Inc. will post -3.79 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Evercore reissued an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Royal Bank Of Canada reduced their target price on Viridian Therapeutics from $42.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, April 7th. Wall Street Zen downgraded Viridian Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Wells Fargo & Company reduced their target price on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Monday, April 20th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.07.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.